2020
Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
Mohamed S, Johnson GR, Sevilimedu V, Rao SD, Hicks PB, Chen P, Lauro K, Jurjus G, Pilkinton P, Davis L, Wilcox JA, Iranmanesh A, Sapra M, Aslam M, Michalets J, Thase M, Zisook S. Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32603560, DOI: 10.4088/jcp.19m13038.Peer-Reviewed Original ResearchConceptsConcurrent posttraumatic stress disorderMajor depressive disorderPosttraumatic stress disorderDepressive disorderVeterans Health Administration medical centersNonpsychotic major depressive disorderStress disorderMini International Neuropsychiatric InterviewAdequate antidepressant treatmentPoor overall outcomeDepressive Symptomatology-Clinician RatedSevere depressive symptomsAntipsychotic augmentationInitial remissionAntidepressant treatmentSuboptimal responseAntipsychotic aripiprazoleCurrent antidepressantsAntidepressant trialsQuick InventoryNeuropsychiatric InterviewClinical trialsMedical CenterRemissionDepressive symptoms
2016
Supported employment and education in comprehensive, integrated care for first episode psychosis: Effects on work, school, and disability income
Rosenheck R, Mueser KT, Sint K, Lin H, Lynde DW, Glynn SM, Robinson DG, Schooler NR, Marcy P, Mohamed S, Kane JM. Supported employment and education in comprehensive, integrated care for first episode psychosis: Effects on work, school, and disability income. Schizophrenia Research 2016, 182: 120-128. PMID: 27667369, DOI: 10.1016/j.schres.2016.09.024.Peer-Reviewed Original ResearchConceptsCommunity carePublic support incomeFirst episode psychosis programUsual community careGeneral estimation equation modelsFirst-episode psychosisEstimation equation modelsPsychosis programPublic support paymentsEpisode psychosisTreatment clinicsDays of participationTreatment approachesFEP participantsIntegrated careStudy participantsTreatment programEvidence effectivenessMonthly assessmentsGroup differencesIndividual PlacementDisability incomeGreater improvementGreater increaseCare
2015
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia
Mohamed S, Rosenheck RA, Lin H, Swartz M, McEvoy J, Stroup S. Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2015, 203: 486-492. PMID: 26075840, DOI: 10.1097/nmd.0000000000000317.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlcoholismAntipsychotic AgentsBenzodiazepinesChronic DiseaseComorbidityCross-Sectional StudiesDibenzothiazepinesDouble-Blind MethodFemaleHumansIllicit DrugsMaleMiddle AgedOlanzapinePerphenazinePiperazinesPsychiatric Status Rating ScalesQuetiapine FumarateRisperidoneSchizophreniaSchizophrenic PsychologySmokingSmoking PreventionSubstance-Related DisordersThiazolesYoung AdultConceptsSecond-generation antipsychotic drugsAntipsychotic drugsFirst-generation antipsychoticsSecond-generation antipsychoticsIntervention Effectiveness (CATIE) studySecondary outcome dataClinical Antipsychotic TrialsFirst-generation drugsSubstance use outcomesCigarette smokingSchizophrenia trialsChronic schizophreniaAntipsychotic TrialsOutcome dataNicotine useDrug useSecondary analysisPast weekAntipsychoticsEffectiveness studiesPatientsSubstance useUse outcomesTrialsDrugs
2014
Association of symptom severity, insight and increased pharmacologic side effects in acutely hospitalized patients with schizophrenia
Zhang J, Rosenheck R, Mohamed S, Zhou Y, Chang Q, Ning Y, He H. Association of symptom severity, insight and increased pharmacologic side effects in acutely hospitalized patients with schizophrenia. Comprehensive Psychiatry 2014, 55: 1914-1919. PMID: 25217308, DOI: 10.1016/j.comppsych.2014.07.018.Peer-Reviewed Original ResearchConceptsPharmacologic side effectsSevere side effectsGreater medication complianceHigher medication dosagesPANSS total scoreSevere symptomsSide effectsMedication complianceMedication dosageITAQ scoresHigh dosesTotal scorePoor treatment complianceSide effect scoresLarge psychiatric hospitalRelationship of symptomsNegative Syndrome ScaleTreatment Attitudes QuestionnaireStepwise multiple linear regression analysisInteraction of symptomsInsightful patientsTreatment emergentHospital dischargePrescribed medicationsTreatment compliance
2010
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. The Journal Of Clinical Psychiatry 2010, 72: 75-80. PMID: 20868641, PMCID: PMC5052810, DOI: 10.4088/jcp.09m05258gre.Peer-Reviewed Original ResearchConceptsMajor depressive episodeSecond-generation antipsychoticsDSM-IV-defined schizophreniaCurrent major depressive episodeClinical practice recommendationsTrial of treatmentClinical practice guidelinesTreatment of depressionCalgary Depression ScaleClinical Antipsychotic TrialsSecond-generation drugsSymptoms of depressionPhase 1 analysisTardive dyskinesiaDepressive episodeChronic schizophreniaAntipsychotic TrialsPractice guidelinesDepression ScaleDepressive symptomsTreatment groupsBaseline scoresPatientsAntipsychoticsPractice recommendations
2008
Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia
Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. Schizophrenia Bulletin 2008, 35: 336-346. PMID: 18586692, PMCID: PMC2659303, DOI: 10.1093/schbul/sbn067.Peer-Reviewed Original ResearchConceptsPositive medication attitudesMedication attitudesSymptoms of schizophreniaSchizophrenia symptomsGreater medication complianceDrug Attitude InventoryRelationship of insightClinical Antipsychotic TrialsTreatment Attitudes QuestionnaireGreater patient understandingLevel of depressionMixed model regression analysisLower symptom levelsRecovery-oriented servicesClinical outcomesMedication adherenceMedication complianceChronic schizophreniaAntipsychotic TrialsPatient understandingModel regression analysisMedicationsCommunity functioningPsychosocial rehabilitationSymptomsRelationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia
Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS. Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia. American Journal Of Psychiatry 2008, 165: 978-987. PMID: 18450928, DOI: 10.1176/appi.ajp.2008.07111713.Peer-Reviewed Original Research
1999
An MRI study of the basal ganglia in autism
Sears L, Vest C, Mohamed S, Bailey J, Ranson B, Piven J. An MRI study of the basal ganglia in autism. Progress In Neuro-Psychopharmacology And Biological Psychiatry 1999, 23: 613-624. PMID: 10390720, DOI: 10.1016/s0278-5846(99)00020-2.Peer-Reviewed Original ResearchConceptsMRI studiesSecond MRI studyTotal brain volumeHigh-resolution MRI scansBasal gangliaGlobus pallidusHealthy controlsCaudate nucleusBilateral caudateCaudate volumeBrain volumeMRI scansCaudate abnormalitiesCaudateVolumetric measurementsRepetitive behaviorsEnlargementAutismSubjectsManual tracingIndependent samplesGangliaPutamenPallidusAbnormalities